9781447142638.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

9781447142638.Pdf Gout David S. Newcombe Gout Basic Science and Clinical Practice Edited by Dwight R. Robinson Author Editor David S. Newcombe, M.D. Dwight R. Robinson, M.D. Weston Department of Rheumatology Massachusetts Massachusetts General Hospital USA Boston USA ISBN 978-1-4471-4263-8 ISBN 978-1-4471-4264-5 (eBook) DOI 10.1007/978-1-4471-4264-5 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2012950015 © Springer-Verlag London 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, speci fi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on micro fi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied speci fi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a speci fi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) This book is dedicated to Dr. Newcombe’s daughters: Catherine L. Newcombe, Kirsten N. Shilling and Sarah N. Faucett. Preface One might ask why a book devoted to a single disorder like gout is necessary since standard textbooks adequately review the usual clinical fi ndings and management of this disorder. The answer to that question is multifaceted. Gout is now clearly associated with several different clinical presentations that are often not described in detail in modern textbooks. Familial juvenile hyperuricemic nephropathy, autosomal dominant polycystic kidney disease, glycogen storage disease, and other disorders associated with hyperuricemia and gout are dysfunctions that need to be recognized early to avoid serious consequences. These and other clinical subsets of gout, in some cases, have also been de fi ned at the molecular level. Such advances in molecular biology provide another rationale for amplifying a physician’s knowledge of gout and the mechanisms of in fl ammation associated with this disease. Furthermore, the in fl ammatory and anti-in fl ammatory mediators, their mechanisms of action, and their real and putative roles in gout have recently been elucidated in greater detail and contribute to a better understanding of the pathogenesis of gout. Such new discoveries also provide a perspective on the capacity of the host to generate natural anti-in fl ammatory molecules, and such data may lead to new therapeutic initiatives. Uric acid, the precursor of gout, has also begun to attain more signi fi cance in relation to renal disease, hypertension, and obesity, and these interrelationships have been characterized in specialty journals but are not linked to textbook discussions of hyperuricemia and gout. These fi ndings alert the physician to evaluate uric acid associated disorders such as hypertension and obesity more extensively than has been the custom previously. Perhaps of greatest signi fi cance to the subjects of hyperuricemia and gout are the epidemiological studies showing that fewer than 10% of patients with gout are referred to rheumatologists. This circumstance leads to multiple errors in the management of this disease by physicians as well as patients. For example, the literature clearly documents the misuse of allopurinol since a number of patients are prescribed this agent for inappropriate reasons. Treating asymptomatic hyperuricemia with allopurinol in the absence of a sound rationale for the reduction in uric acid levels places patients at risk for the serious side effects of this agent including renal failure and even death. In addition, allopurinol has also been used as the sole agent for the treatment of acute gouty arthritis in elderly patients suffering from diuretic-induced gout as well as in other inappropriate settings where allopurinol is not indicated. Although uric acid is often the precursor of acute gouty arthritis, allopurinol vii viii Preface has no role in the management of acute gouty arthritis since it has no effect on an acute in fl ammatory response. Patients with hand deformities due to extensive tophaceous deposits may often be mistakenly diagnosed as rheu- matoid arthritis, and the need for the reduction of tophaceous deposits com- pletely ignored. Neglecting the treatment of chronic tophaceous gout may have serious consequences such as the collapse of a urate-laden vertebra or aseptic necrosis of the hip. Another important aspect of gout in modern times is the increasing identi fi cation of genetic dysfunctions associated with hyperuricemia and gout. Thus, a family history becomes a critical part of the evaluation of the hyperuricemic patient and avoids the pitfalls related to a delay in the early detection and treatment of affected family members. Often a cooperative patient who researches the family for underlying disorders may provide the physician with a most rewarding experience and be most useful in the early treatment of family members. The contents of this monograph provide the practicing physician with a ready source of information concerning hyperuricemia and gout as well as discussions of the management goals for the optimal treatment of these disorders. About the Author David Sugden Newcombe, M.D., graduated from Amherst College in 1952, cum laude in Biology. He received his medical degree from McGill University in 1956. Dr. Newcombe did his postdoctoral training at Boston City Hospital, Duke University, Boston University, and the Peter Brent Brigham Hospital at Harvard. He completed his military service in Korea in 1958. From 1965 to 1967, he was an Assistant Professor of Medicine at the University of Virginia. He then served as an Associate Professor of Medicine at the University of Vermont where he subsequently became the Director of Rheumatology. In 1977, he went to The Johns Hopkins University where he rose to the rank of Professor of Environmental Health Science in the University’s School of Hygiene and Public Health and held a Joint Appointment in the Department of Medicine in the University’s School of Medicine. Upon retiring from Johns Hopkins in 1992, he moved to Massachusetts where he was Associate Chief of Staff at the Bedford Veterans Administration Hospital until 1999. He then served as an Associate Physician at the Federal Medical Center (Devens) Massachusetts until he retired in 2001. Dr. Newcombe wrote two books: Inherited Biochemical Disorders and Uric Acid Metabolism (1975 University Park Press) and Clinical Immunotoxicology (1992 Raven Press). He also authored over one hundred medical and scientifi c articles. At the time of his retirement, Dr. Newcombe began the project that eventu- ally became this book on gout. He had a life-long interest in the disease and its complexities. The 1,000 page manuscript was completed just fi ve days before his death. Almost a year later his family requested that Dr. Robinson arrange for the publication of his work. The manuscript was then modi fi ed and updated. At this time the book represents the most comprehensive publi- cation available on gout, which is the world’s most common in fl ammatory rheumatic disease. The Editor, Dwight R. Robinson, M.D., is a rheumatologist at the Massachusetts General Hospital and Professor of Medicine, Harvard Medical School. ix Acknowledgment The Newcombe family is profoundly grateful to Dr. Dwight Robinson. Dr. Newcombe’s manuscript on gout would never have been published had it not been for Dr. Robinson’s expert knowledge of this disease and his unwav- ering dedication to the substantial task of editing the valuable piece of medi- cal scholarship that Dr. Newcombe produced. xi Contents 1 A Brief History of Gout ................................................................. 1 Egyptian Archeology ....................................................................... 1 Byzantine Empire ............................................................................. 2 Seventeenth Century ........................................................................ 2 Eighteenth Century........................................................................... 2 Nineteenth Century .......................................................................... 4 Twentieth Century ...........................................................................
Recommended publications
  • Phosphorylation of Mcardle Phosphorylase Induces Activity (Human Skeletal Muscle/Protein Kinase) CESARE G
    Proc. Nati. Acad. Sci. USA Vol. 78, No. 5, pp. 2688-2692, May 1981 Biochemistry Phosphorylation of McArdle phosphorylase induces activity (human skeletal muscle/protein kinase) CESARE G. CERRI AND JOSEPH H. WILLNER Department of Neurology and H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032 Communicated by Harry Grundfest, January 7, 1981 ABSTRACT In McArdle disease, myophosphorylase defi- mediate between those of phosphorylases b and a. Karpatkin ciency, enzyme activity is absent but the presence of an altered et al. (19, 20) found that incubation of human platelets with enzyme protein can frequently be demonstrated. We have found MgATP+ resulted in an increase in total phosphorylase activity that phosphorylation of this protein in vitro can result in catalytic and concluded that the data were "consistent with the presence activity. We studied muscle of four patients; all lacked myophos- in human platelets of inactive dimer and monomer species of phorylase activity, but myophosphorylase protein was demon- phosphorylase, which require MgATP for activation." Because strated by immunodiffusion or gel electrophoresis. Incubation of activation of these isozymes was probably due to protein phos- muscle homogenate supernatants with cyclic AMP-dependent pro- phorylation and also because incomplete phosphorylation could tein kinase and ATP resulted in phosphorylase activity. The ac- tivated enzyme comigrated with normal human myophosphory- result in reduced activity, we evaluated the possibility that the lase in gel electrophoresis. Incubation with [y-32P]ATP resulted activity ofphosphorylase in McArdle muscle could be restored in incorporation of 32P into the band possessing phosphorylase by phosphorylation of the inactive phosphorylase protein pres- activity.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Statistical Mechanics of Allosteric Enzymes
    Statistical Mechanics of Allosteric Enzymes Tal Einav,† Linas Mazutis,‡ and Rob Phillips∗,¶ Department of Physics, California Institute of Technology, Pasadena, California 91125, United States, Institute of Biotechnology, Vilnius University, Vilnius, Lithuania, and Department of Applied Physics and Division of Biology, California Institute of Technology, Pasadena, California 91125, United States E-mail: [email protected] Abstract The concept of allostery in which macromolecules switch between two different conforma- tions is a central theme in biological processes ranging from gene regulation to cell signaling to enzymology. Allosteric enzymes pervade metabolic processes, yet a simple and unified treatment of the effects of allostery in enzymes has been lacking. In this work, we take the first step towards this goal by modeling allosteric enzymes and their interaction with two key molecular players - allosteric regulators and competitive inhibitors. We then apply this model to characterize existing data on enzyme activity, comment on how enzyme parameters (such as substrate binding affinity) can be experimentally tuned, and make novel predictions on how to control phenomena such as substrate inhibition. arXiv:1701.03988v1 [q-bio.SC] 15 Jan 2017 ∗To whom correspondence should be addressed †Department of Physics, California Institute of Technology, Pasadena, California 91125, United States ‡Institute of Biotechnology, Vilnius University, Vilnius, Lithuania ¶Department of Applied Physics and Division of Biology, California Institute
    [Show full text]
  • The Politics of Beer: Analysis of the Congressional Votes on the Beer Bill of 1933
    Public Choice https://doi.org/10.1007/s11127-017-0493-1 The politics of beer: analysis of the congressional votes on the beer bill of 1933 1 2 3 Eline Poelmans • John A. Dove • Jason E. Taylor Received: 26 June 2017 / Accepted: 4 December 2017 Ó Springer Science+Business Media, LLC, part of Springer Nature 2017 Abstract Nine days after he took office in March 1933, Franklin Roosevelt asked Con- gress to amend existing federal Prohibition policy so as to allow for the sale and con- sumption of 3.2% alcohol beer. Over the following 8 days, the so-called ‘‘beer bill’’ was proposed, debated, passed and signed into law. This study analyzes the political decision making behind one of FDR’s earliest New Deal policies. Specifically, we consider how voter preferences, representatives’ ideologies, national party affiliations, and the influence of special interests affected legislative decision making. We find that special interests and party affiliations were particularly important drivers of congressional voting behavior. Keywords Beer legalization Á Prohibition Á Special interests Á Median voter Á Representative ideology Á New Deal Á Franklin Roosevelt Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11127-017- 0493-1) contains supplementary material, which is available to authorized users. & Jason E. Taylor [email protected] Eline Poelmans [email protected] John A. Dove [email protected] 1 LICOS Centre for Institutions and Economic Performance, Faculty of Economics and Business, Campus Brussels,
    [Show full text]
  • Lec-08-Handout
    NPTEL VIDEO COURSE – PROTEOMICS PROF. SANJEEVA SRIVASTAVA HANDOUT LECTURE-08 ENZYME: BASIC CONCEPTS, CATALYTIC AND REGULATORY STRATEGIES Slide 1 Today, we will talk about enzyme: basic concepts, catalytic and regulatory strategies. Slide 2 Lecture outline: • Basic concepts of enzyme including enzyme kinetics, energetics and enzyme inhibition. • Different type of catalytic strategies and regulatory strategies. Slide 3 So as you all know, enzymes play very important role in biochemistry All enzymes are proteins therefore it will essential to study about enzymes while studying basic concepts of amino acids and proteins. Although it may not be directly linked to the proteomics but understanding of enzyme and proteins is very fundamental for the advanced understanding of concepts related to proteomics. Slide 4 So what are enzymes? • Enzymes are molecular catalysts. • Almost all enzymes are proteins and as we have discussed in the previous lecture there are twenty amino acids that make up the basic building blocks of all proteins. • Enzymes can accelerate a given reaction up to million folds. Let’s take an example of carbonic anhydrase which catalyzes hydration of carbon di oxide. Now this enzyme can catalyze 106 molecules per second. • Enzymes are highly specific and catalyze single or closely related reaction. DEPARTMENT OF BIOSCIENCES & BIOENGINEERING INDIAN INSTITUTE OF TECHNOLOGY (IIT) BOMBAY, MUMBAI, INDIA Page 1 NPTEL VIDEO COURSE – PROTEOMICS PROF. SANJEEVA SRIVASTAVA Slide 5 In terms of enzyme specificity, let me give you few examples- • Trypsin- it is highly specific, it cleaves peptide on carboxyl side of Lys/Arg. • Another enzyme thrombin, which participates in blood clotting, it is even more specific that trypsin.
    [Show full text]
  • (Glycogen Storage Disease Type V) and Anesthesia a Case Report And
    Pediatric Anesthesia ISSN 1155-5645 REVIEW ARTICLE McArdle’s disease (glycogen storage disease type V) and anesthesia – a case report and review of the literature Georg Bollig1,2 1 Department of Anesthesiology and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, Schleswig, Germany 2 Department of Surgical Sciences, Haukeland University Hospital, University of Bergen, Bergen, Norway Keywords Summary general anesthesia; glycogen storage disease; glycogen storage disease type V; McArdles disease (glycogen storage disease type v) is a rare condition in malignant hyperthermia; McArdles disease; which energy-metabolism in the muscle is hampered. A case report is pre- perioperative complications sented and the possible risk for perioperative complications including malig- nant hyperthermia is discussed. A checklist for the anesthesiological Correspondence management of patients with McArdles disease is provided. A short overview Georg Bollig, Department of Anesthesiology of anesthesiological challenges and perioperative complications of other gly- and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, cogen storage diseases is given. Schleswig, Germany Email: [email protected] Section Editor: Barbara Brandom Accepted 3 March 2013 doi:10.1111/pan.12164 tachycardia and hypotonia occurred. After the opera- Introduction tion, the anesthesiologist informed the patient about the McArdle’s disease is a rare condition in which energy event and the fact that he had elevated liver enzymes metabolism in the muscle is hampered. A case report (aspartate transaminase = AST, alanine transaminase = will be presented, and the possible risk of perioperative ALT, and lactate dehydrogenase = LDH). An overview problems including malignant hyperthermia is dis- of the patient’s anesthesiological history is given in cussed.
    [Show full text]
  • Structure and Evolution of Protein Allosteric Sites
    Structure and evolution of protein allosteric sites by Alejandro Panjkovich Thesis submitted to Universitat Aut`onoma de Barcelona in partial fulfillment of the requirements for the degree of Doctor of Philosophy Director - Prof. Xavier Daura Tesi Doctoral UAB/ANY 2013 Ph.D. Program - Protein Structure and Function Institut de Biotecnologia i Biomedicina caminante, no hay camino, se hace camino al andar Antonio Machado,1912 Acknowledgements First of all I would like to thank my supervisor and mentor Prof. Xavier Daura for his consistent support and trust in my work throughout these years. Xavi, I deeply appreciate the freedom you gave me to develop this project while you were still carefully aware of the small details. Working under your supervision has been a rich and fulfilling experience. Of course, thanks go as well to current and past members of our institute, especially Rita Rocha, Pau Marc Mu˜noz,Oscar Conchillo, Dr. Mart´ınIndarte, Dr. Mario Ferrer, Prof. Isidre Gibert, Dr. Roman Affentranger and Dr. Juan Cedano for their technical and sometimes philo- sophical assistance. Help from the administrative staff was also significant, I would like to thank in particular Eva, Alicia and Miguel who where always ready to help me in sorting out unexpected bureaucratic affairs. I would also like to thank Dr. Mallur Srivatasan Madhusudhan and his group (especially Kuan Pern Tan, Dr. Minh Nguyen and Binh Nguyen), and also Dr. Gloria Fuentes, Cassio Fernandes, Youssef Zaki, Thijs Kooi, Rama Iyer, Christine Low and many others at the Bioinformatics Institute BII - A∗STAR in Singapore for the many interesting discussions and support during my stage over there.
    [Show full text]
  • Guaiacol As a Drug Candidate for Treating Adult Polyglucosan Body Disease
    Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon, … , Wyatt W. Yue, H. Orhan Akman JCI Insight. 2018;3(17):e99694. https://doi.org/10.1172/jci.insight.99694. Research Article Metabolism Therapeutics Graphical abstract Find the latest version: https://jci.me/99694/pdf RESEARCH ARTICLE Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon,1 Igor Ferreira,2 Leonardo J. Solmesky,3 Netaly Khazanov,4 Alexander Lossos,1 Rafael Alvarez,5 Deniz Yetil,6 Sergey Pampou,7 Miguel Weil,3,8 Hanoch Senderowitz,4 Pablo Escriba,5 Wyatt W. Yue,2 and H. Orhan Akman9 1Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.3 Cell Screening Facility for Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 4Department of Chemistry, Bar Ilan University, Ramat Gan, Israel. 5Laboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain. 6Connecticut College, Newington, Connecticut USA. 7Columbia University Department of Systems Biology Irving Cancer Research Center, New York, New York, USA. 8Laboratory for Neurodegenerative Diseases and Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty for Life Sciences, Sagol School of Neurosciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 9Columbia University Medical Center Department of Neurology, Houston Merritt Neuromuscular diseases research center, New York, New York, USA. Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency.
    [Show full text]
  • Table S1. List of Genes Up- Or Down-Regulated in H99 When Bound by 18B7
    Table S1. List of genes up- or down-regulated in H99 when bound by 18B7. Up-regulated Genes Classification CNF03470: Formate dehydrogenase Metabolism CNC03960: Phosphate transporter, putative Metabolism CND00530: Putative urea transporter Secretion CNA02250: Ammonium transporter MEP1 Secretion CNC06440: Inositol 1-phosphate synthase Metabolism CND03490: Chitin deacetylase-like mannoprotein MP98 Cell wall CNA04560: Hypothetical protein Hypothetical CNF02180: Acetyl-CoA carboxylase, putative Metabolism CNJ00690: Uracil permease, putative Secretion CNF02510: Alcohol dehydrogenase, putative Metabolism CNE04360: Fatty acid synthase, alpha subunit-related Metabolism CNM00180: Cyclohydrolase, putative Metabolism CNL03740: AF540951 catalase isozyme P Stress CNE04370: Fatty acid synthase, beta subunit Metabolism CNA01790: Expressed protein Hypothetical CNA05700: Expressed protein Hypothetical CND03840: Vacuole fusion, non-autophagic-related protein, putative Cell wall CNM00980: Hypothetical protein Hypothetical CNI02420: Uricase (Urate oxidase), putative Metabolism CNJ01090: Xylitol dehydrogenase-related Cell wall CNC03430: Alpha-1,6-mannosyltransferase, putative Cell wall CNF04120: Expressed protein Hypothetical CNB01810: Short chain dehydrogenase, putative Metabolism CNJ01200: Hypothetical protein Hypothetical CNA01160: LSDR putative Metabolism CNH03430: Hypothetical protein Hypothetical CNM02410: Putative proteine disulfate isomerase Housekeeping CNG04200: Alpha-amylase, putative Cell wall CNC00920: NADP-dependent glutamate dehydrogenase Metabolism
    [Show full text]
  • Metabolism of Glycogen Glycogenesis
    LEC: 10Biochemistry Dr. Anwar J Almzaiel Metabolism of glycogen Glycogen is the major storage form of carbohydrate in animal and corresponds to starch in plant. It occurs mainly in liver (up to 6%) and muscle(up to 1%). However, because of great mass, muscle represents some 3-4 times as much as glycogen store as liver. It is branched polymer of α- glucose. The function of muscle glycogen is to act as a readily available source of hexose units for glycolysis within the muscle itself. Liver glycogen is largely concerned with storage and export of hexose units for maintenance of the blood glucose, particularly between meals. After (12-18 hours) of fasting, the liver becomes almost totally depleted of glycogen, whereas muscle glycogen is only depleted significantly after prolonged various exercise. Why the cell can store glycogen but not glucose? Because when glucose increased, osmatic pressure in the cell increase, causing water movement toward the cell and leading to burst so when glucose accumulates in the cell, it will convert to glycogen which consists of branched series of glucose. Glycogenesis The process of glycogenesis start when glucose-6-phosphat is changed to glucose-1-phosphate by mutase mutas glucose-6-phosphatglucosee 1-phosphate The reaction is reversible and depends on concentration of substrate (glucose- 6-phosphat), if there is a large amount or quantities of glucose-6-phosphat will lead to formation of glucose 1-phosphate and the opposite is right. No loss in the energy in this reaction As glucose 1-phosphate formed, it will react with high energy compound UTP (uradin triphosphate), which react with glucose to give UDP glucose (uradin diphosphate glucose) and pyrophosphate released glucose 1-phosphate is high energetic compound and called (active glucose molecule), this reaction is carried by (UDP glucose pyrophosphorylase) 1 LEC: 10Biochemistry Dr.
    [Show full text]
  • Nucleotide Metabolism 22
    Nucleotide Metabolism 22 For additional ancillary materials related to this chapter, please visit thePoint. I. OVERVIEW Ribonucleoside and deoxyribonucleoside phosphates (nucleotides) are essential for all cells. Without them, neither ribonucleic acid (RNA) nor deoxyribonucleic acid (DNA) can be produced, and, therefore, proteins cannot be synthesized or cells proliferate. Nucleotides also serve as carriers of activated intermediates in the synthesis of some carbohydrates, lipids, and conjugated proteins (for example, uridine diphosphate [UDP]-glucose and cytidine diphosphate [CDP]- choline) and are structural components of several essential coenzymes, such as coenzyme A, flavin adenine dinucleotide (FAD[H2]), nicotinamide adenine dinucleotide (NAD[H]), and nicotinamide adenine dinucleotide phosphate (NADP[H]). Nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), serve as second messengers in signal transduction pathways. In addition, nucleotides play an important role as energy sources in the cell. Finally, nucleotides are important regulatory compounds for many of the pathways of intermediary metabolism, inhibiting or activating key enzymes. The purine and pyrimidine bases found in nucleotides can be synthesized de novo or can be obtained through salvage pathways that allow the reuse of the preformed bases resulting from normal cell turnover. [Note: Little of the purines and pyrimidines supplied by diet is utilized and is degraded instead.] II. STRUCTURE Nucleotides are composed of a nitrogenous base; a pentose monosaccharide; and one, two, or three phosphate groups. The nitrogen-containing bases belong to two families of compounds: the purines and the pyrimidines. A. Purine and pyrimidine bases Both DNA and RNA contain the same purine bases: adenine (A) and guanine (G).
    [Show full text]
  • SUPPY Liglucosexlmtdh
    US 20100314248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0314248 A1 Worden et al. (43) Pub. Date: Dec. 16, 2010 (54) RENEWABLE BOELECTRONIC INTERFACE Publication Classification FOR ELECTROBOCATALYTC REACTOR (51) Int. Cl. (76) Inventors: Robert M. Worden, Holt, MI (US); C25B II/06 (2006.01) Brian L. Hassler, Lake Orion, MI C25B II/2 (2006.01) (US); Lawrence T. Drzal, Okemos, GOIN 27/327 (2006.01) MI (US); Ilsoon Lee, Okemo s, MI BSD L/04 (2006.01) (US) C25B 9/00 (2006.01) (52) U.S. Cl. ............... 204/403.14; 204/290.11; 204/400; Correspondence Address: 204/290.07; 427/458; 204/252: 977/734; PRICE HENEVELD COOPER DEWITT & LIT 977/742 TON, LLP 695 KENMOOR, S.E., PO BOX 2567 (57) ABSTRACT GRAND RAPIDS, MI 495.01 (US) An inexpensive, easily renewable bioelectronic device useful for bioreactors, biosensors, and biofuel cells includes an elec (21) Appl. No.: 12/766,169 trically conductive carbon electrode and a bioelectronic inter face bonded to a surface of the electrically conductive carbon (22) Filed: Apr. 23, 2010 electrode, wherein the bioelectronic interface includes cata lytically active material that is electrostatically bound directly Related U.S. Application Data or indirectly to the electrically conductive carbon electrode to (60) Provisional application No. 61/172,337, filed on Apr. facilitate easy removal upon a change in pH, thereby allowing 24, 2009. easy regeneration of the bioelectronic interface. 7\ POWER 1 - SUPPY|- LIGLUCOSEXLMtDH?till pi 6.0 - esses&aaaas-exx-xx-xx-xx-xxxxixax-e- Patent Application Publication Dec. 16, 2010 Sheet 1 of 18 US 2010/0314248 A1 Potential (nV) Patent Application Publication Dec.
    [Show full text]